JAMA+ Trials

📝 JAMA+ Trials: Trial Theme of the Month This month, JAMA+ Trials highlights de-escalation, discontinuation, and de-implementation trials, a growing area of research focused on evaluating when and how health care interventions can be reduced, stopped, or streamlined while maintaining—or even improving—patient outcomes. Read the Editorial by JAMA+ Trials Editor in Chief Alison Huang, MD, MAS, Mara Schonberg, MD, MPH, and JAMA Internal Medicine Deputy Editor Deborah Grady, MD, MPH: https://ja.ma/4wJvCwP ➡️ From JAMA Neurology: The DOT-MS RCT examined whether patients with stable #disease could safely discontinue first-line disease-modifying therapy. https://ja.ma/4vLsC2A ➡️ From JAMA: The SURMOUNT-4 RCT investigated whether continued #tirzepatide treatment is necessary to maintain weight reduction after initial success. https://ja.ma/4vGH5Nh ➡️ From JAMA Psychiatry: Researchers evaluated early dose reduction or discontinuation of #antipsychotic #medications following remission after a first psychotic episode. https://ja.ma/44IKgbn ➡️ From JAMA Oncology: The DEPEND Phase 2 Clinical Trial explored a response-stratified approach to #chemoradiation therapy in HPV-negative head and neck #cancer, examining opportunities to tailor treatment intensity. https://ja.ma/4fg1MKe ➡️ From JAMA Internal Medicine: A RCT examined whether a masked taper paired with a behavioral intervention could support discontinuation of #benzodiazepine receptor agonists. https://ja.ma/44O6jNO ➡️ From JAMA Network Open: A cluster RCT evaluated strategies to deimplement #opioid prescribing in primary care, addressing a critical challenge in evidence-based practice change. https://ja.ma/4p3jfJf Explore the full Trial Theme of the Month and learn more about JAMA+ Trials, your destination for discovering, understanding, and discussing clinical trials across the JAMA Network: https://ja.ma/4xU3w34

In JAMA+ Trials, we spotlight meta-research from JAMA Network Open examining strategies to improve trial participation and informed consent. In a randomized clinical trial involving more than 1500 participants, investigators evaluated whether audiovisual enhancements to electronic consent increased consent rates or improved comprehension compared with text-only formats. These findings offer new insights into participant engagement and the potential for multimedia consent interventions highlighted by JAMA+ Trials. 📖 Read the full trial in JAMA Network Open: https://ja.ma/4uKV4Ao 📬 Sign up for the JAMA+ Trials email newsletter: https://ja.ma/4vsNn3c

JAMA+ Trials explores recent meta-research published in JAMA Network Open that addresses a common question in clinical trial operations: what recruitment strategies actually work? In a randomized clinical trial of over 15 000 potential participants, researchers compared email outreach and patient portal messaging to determine which method led to higher trial enrollment. Discover which approach proved most effective for engaging potential participants in clinical trials in this edition of JAMA+ Trials. 📖 Read the full trial in JAMA Network Open: https://ja.ma/4oBAL6W 📬 Sign up for the JAMA+ Trials email newsletter: https://ja.ma/4ejBuX8

This week in JAMA+ Trials, the Editor’s Choice for Clinical Trial of 2025 is introduced by Kanade Shinkai, MD, PhD, Editor of JAMA Dermatology. In her accompanying note and video, Dr Shinkai describes the CASCADE trial of emollient therapy for pediatric eczema prevention as “impressive”—noting the innovative use of decentralized methods that enabled engagement of diverse parent-infant dyads within primary care. 📬 Sign up for the JAMA+ Trials email newsletter: https://ja.ma/4axnoik 📖 Read the full trial in JAMA Dermatology: https://ja.ma/3SmqIXt 📝 Read the Editor's Note: https://ja.ma/4uNu6by

A randomized clinical trial published in JAMA Dermatology evaluated daily emollient use beginning before age 9 weeks for the prevention of #AtopicDermatitis in US infants not selected for risk. Assignment to daily moisturizer reduced eczema incidence by 16% at age 2 years, with safety demonstrated across a large, diverse cohort. JAMA Dermatology Editor in Chief Kanade Shinkai, MD, PhD, named this trial Editor’s Choice for its methodological rigor, inclusion of underrepresented populations, and ability to inform #clinical and #policy approaches to pediatric #Eczema. The study highlights the importance of large, community-based randomized controlled trials in guiding evidence-based practice. 📌 How can clinicians and researchers stay up to date on the most clinically relevant trials? JAMA+ Trials highlights the implications and innovations of clinical trial research from across the JAMA Network to advance evidence-based medicine and public health. Follow JAMA+ Trials to get curated access to the best of the JAMA Network’s trial research, commentaries, and educational resources. 📬 Sign up for the JAMA+ Trials email newsletter: https://ja.ma/4axnoik 📖 Read the full trial in JAMA Dermatology: https://ja.ma/4oEOIkN 📝 Read the Editor's Note by Kanade Shinkai, MD, PhD, JAMA Dermatology Associate Editor John Barbieri, MD, MBA, and JAMA+ Trials Editor in Chief Alison Huang, MD, MAS, MPhil: https://ja.ma/4oD7s4b

This week in JAMA+ Trials, we introduce a new Theme of the Month: Trials That Inform Health Policy—A Bridge Too Far? In an Editorial co-authored with Dr Sandro Galea, MD, DrPH, Editor of JAMA Health Forum, we explore whether trial evidence can successfully guide policy decisions about health care delivery, population health interventions, and health system reform—or whether fundamental tensions make this an impossible goal. 💬 Read the Editorial: https://ja.ma/4giHP6k 📬 Sign up for the JAMA+ Trials email newsletter: https://ja.ma/4cdJw2P

This week in JAMA+ Trials, we introduce a new Theme of the Month: Trials That Inform Health Policy—A Bridge Too Far? 📌 Learn more about the Trial Theme of the Month: https://ja.ma/4emQORG Explore this month's theme to see how trialists are navigating the challenge of generating policy-relevant evidence—and decide for yourself whether trial research and policymaking can successfully bridge the gap. 📬 Sign up for the JAMA+ Trials email newsletter: https://ja.ma/4cdJw2P

A randomized clinical trial published in JAMA Pediatrics evaluated the Nurse-Family Partnership (NFP) program among #Medicaid-eligible pregnant people in South Carolina to determine its impact on early #childhood #health and health care utilization outcomes. Assignment to intensive nurse home visiting did not result in statistically significant improvements in the composite primary outcome of child mortality, injury, or concern for abuse or neglect, nor in emergency department utilization or receipt of guideline-recommended well-child visits. These findings contrast with earlier, smaller trials and highlight the challenges of improving adverse childhood experiences through large-scale interventions within Medicaid. JAMA Pediatrics Editor in Chief Dimitri Christakis, MD, MPH, selected this #trial for its rigor, contemporary relevance, and potential to guide #clinical and #policy decision-making around #nurse home visiting programs. The study demonstrates the value of large, population-based randomized controlled trials in shaping evidence-based practice, including when findings are negative. 📌 How can clinicians and researchers stay up to date on the most clinically relevant trials? JAMA+ Trials highlights the implications and innovations of clinical trial research from across the JAMA Network to advance evidence-based medicine and public health. Follow JAMA+ Trials to get curated access to the best of the JAMA Network’s trial research, commentaries, and educational resources. 📬 Sign up for the JAMA+ Trials email newsletter: https://ja.ma/4vFlXXz 📖 Read the full trial: https://ja.ma/43lnfuE

This week on JAMA+ Trials with JAMA Health Forum Editor in Chief Sandro Galea, MD, DrPH, we discuss the potential gap between the evidence that clinical trials typically provide and what health policy decisions demand: https://lnkd.in/gFjYdmSF Read in JAMA why so few health policy decisions are made solely, or even primarily, based on evidence from clinical trials: https://lnkd.in/gpF7eCma

#ClinicalTrials persist as the most durable foundation for evidence-based action, despite complex tribulations in funding, recruitment, and protocol management. JAMA+ Trials is a new online platform that attests to the vision and resilience of clinical trial research by offering readers multimedia features, tailored resources on trial methodology, and a searchable collection of trial reports published across the JAMA Network. Through curated access and honest dialogue about challenges and breakthroughs, JAMA+ Trials illuminates the diversity and collective experience of trialists and fosters connection between interventional research and the broader medical community. 📝 Read "A Love Letter to Clinical Trials" by Editor in Chief Alison Huang, MD, MAS: https://lnkd.in/eba9GCMY 📬 Sign up for the JAMA+ Trials email newsletter: https://lnkd.in/eG5ciH6f